Lexaria Bioscience Corp. (LEXX)
After hours:
| Previous Close | 2.6300 |
| Open | 2.6500 |
| Bid | 2.7100 x 100 |
| Ask | 2.8300 x 100 |
| Day's Range | 2.5779 - 2.8297 |
| 52 Week Range | 0.7050 - 6.8500 |
| Volume | |
| Avg. Volume | 233,117 |
| Market Cap | 39.818M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings Date | Jul 12, 2024 - Jul 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
ACCESSWIRELexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces ...
ACCESSWIREDosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
Second study arm dosing is now complete. KELOWNA, BC / ACCESSWIRE / June 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, ...
- ACCESSWIRE
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in ...
